"Pfizer's proposal would dramatically dilute AstraZeneca shareholders' exposure to our unique pipeline and would create risks around its delivery," Chairman Leif Johansson said.
Britain's AstraZeneca on Monday rejected a sweetened and "final" offer from Pfizer , casting serious doubt on the U.S. drugmaker's plan for a merger to create the world's biggest pharmaceuticals group.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances